Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
Date first appeared online 14/11/2019
DOI 10.1111/dom.13896
Authors Bain S.
Journal Name Diabetes, Obesity and Metabolism
Volume 22

Documents